Comparative Pharmacology
Head-to-head clinical analysis: DURAGESIC 12 versus JOBEVNE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURAGESIC 12 versus JOBEVNE.
DURAGESIC-12 vs JOBEVNE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a potent synthetic opioid agonist that primarily binds to mu-opioid receptors in the central nervous system, leading to analgesic effects by increasing potassium conductance and decreasing calcium influx, thereby inhibiting ascending pain pathways and altering pain perception.
JOBEVNE is a monoclonal antibody that binds to and inhibits the activity of a specific cytokine receptor, reducing inflammatory signaling.
Transdermal patch, initially 12 mcg/h applied every 72 hours in opioid-naive patients; titrate based on response and tolerance.
100 mg intravenously every 12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 20–27 hours (range 13–44 hours) after transdermal patch removal; prolonged in elderly, hepatic impairment, and with continuous use due to drug accumulation in skin and adipose tissue.
Terminal half-life: 12-15 hours; clinical context: supports twice-daily dosing in most patients
Renal: approximately 75% as metabolites (primarily norfentanyl and other inactive metabolites) and <10% as unchanged fentanyl; fecal: approximately 9%; biliary: minor.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Category C
Category C
Opioid Analgesic
Opioid Analgesic